Drug Type Small molecule drug |
Synonyms MY-008, MY008, MY008211A + [1] |
Target |
Action inhibitors |
Mechanism CFB inhibitors(Complement factor B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (10 Jun 2026), |
RegulationOrphan Drug (United States), Breakthrough Therapy (China), Priority Review (China) |
Molecular FormulaC27H32N2O4 |
InChIKeyYJJUEZFALZMWAP-URXFXBBRSA-N |
CAS Registry2797066-85-2 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hemoglobinuria, Paroxysmal | China | 10 Jun 2026 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glomerulonephritis, IGA | Phase 2 | China | 30 Nov 2024 | |
| Hemolysis | Phase 2 | China | 06 Jul 2023 | |
| C3 glomerulopathy | IND Approval | China | 18 Dec 2023 | |
| Diabetic Nephropathies | IND Approval | China | 18 Dec 2023 | |
| Idiopathic Membranous Glomerulonephritis | IND Approval | China | 18 Dec 2023 | |
| Lupus Nephritis | IND Approval | China | 18 Dec 2023 |
Phase 3 | 68 | MY008211A 400 mg | yxjatiiudg(nebflofnwr) = The most common adverse events with MY008211A were neutrophil count decreased (29.4%), upper respiratory infection (26.5%), and white blood cell count decreased (23.5%). No major adverse vascular events occurred in either arm. ziqsuenqqi (mtfpvqjmjx ) View more | Positive | 12 May 2026 | ||
Phase 3 | 20 | MY008211A 400 mg | updrvnmfnk(skjcaqvezr) = ysvqbwmtwb zjilzekgwz (xtyubxuiyy ) View more | Positive | 12 May 2026 | ||
Phase 2 | - | ysqaixkvnt(qtmfrtxnba) = n=15 of 34 patients laedaxblec (asgprmhnxn ) View more | - | 08 Dec 2024 | |||





